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ABSTRACT  
 
Background: adherence to inhaled drugs is linked to patients’ satisfaction with their device, and an 
incorrect use can negatively affect the outcomes of asthma treatment. We speculated that this is 
particularly true in elderly asthmatic subjects. 
Aim: we performed a national pre-post interventional multicentre study enrolling moderate-to-
severe asthmatic subjects aged ≥65 yrs treated with fixed inhaled combination drugs by dry 
powder inhaler (DPI) or pressurized metered dose inhaler (pMDI). Adherence and critical errors 
were evaluated by means of validated questionnaires at first visit (V1) and after 3 to 6 months 
(V2). At V1, subjects underwent intensive training on the correct use of their device by physical 
demonstration. 
Results: a total of 411 asthmatics (F/M: 238/173, mean age±SD: 72±5 yrs) participated to the 
study. At V1, 50% of the study subjects showed an Asthma Control Test (ACT) score ≤19 despite 
GINA step 3 and 4 treatment, and 40% had experienced at least one severe asthma exacerbation 
in the previous year. Poor adherence to treatment was recorded in 43% of subjects, and at least 
one error in using the device was registered in 56% of subjects. At V2, available for 318 patients, 
both the percentage of individuals with poor adherence and with at least one critical error 
significantly decreased (from 46% to 25%, and from 49% to 25%, respectively; p<0.001 for both 
comparisons) with a significant increase of the ACT score (from 19±4.9 to 20±4.0, p<0.001).  
Conclusions: asthma in the elderly is characterized by low levels of symptom control. Educational 
interventions are strongly advocated in this age groups in order to increase adherence to 
treatment and inhaler techniques. 
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INTRODUCTION 
Errors in inhaler handling, not taken into account in clinical trials, could impact on drug 
delivery and minimise treatment benefits. Approximate 50 billions USD are spent annually on 
inhalers in the USA, and 7 to 15 billions USD are wasted due to incorrect technique (1). Lewis et al 
(2) developed a model for estimating the impact of poor inhaler technique on the economic 
burden of asthma and COPD in Spain, Sweden and UK, and attributed 2.2% to 2.7% of direct 
asthma and COPD costs to poor inhalation technique in 105 million euros across the three 
countries studied.  
 In a previous study, we reported a high rate of uncontrolled asthma in elderly subjects (3) 
with possible explanations due to the well-known poor perception of dyspnea in the elderly (4) 
and the occurrence of comorbidities; of note, low adherence to therapy or improper use of inhaler 
devices, which are known to be associated with loss of asthma control (5-6), were not explored. 
Among subjects with obstructive airway diseases only less than a quarter are compliant with their 
medications (≥80% of prescribed doses) as reported by the Italian National Health Agency (7). 
Moreover, a correct use of the inhalation devices is essential to ensure the effectiveness of the 
treatment (8), and a high rate of inhalation device mishandling has been reported in younger 
asthmatics, with an impact on asthma control (9-11). It is logical to hypothesize that elderly 
asthmatic patients are more at risk of errors because of the higher frequency of comorbid 
conditions potentially affecting the correct use of the device, as recently reported by Usmani et al 
(12). Interestingly, a recent meta-analysis from Maricoto et al (13) reported a significant effect of 
inhaler educational programs in reducing exacerbations and in improving clinical control, 
specifically in subject aged 65 and older with asthma or COPD. However, the authors also 
admitted to have failed in the attempt to uncover important information about the role of inhaler 
technique alone, due to the fact that studies included in the meta-analysis addressed a large 
variety of interventional approaches, making harder to detect the contribution of incorrect inhaler 
manoeuvres. Also, the majority of the studies did not control for the confounding effect of 
adherence itself, which may be more relevant than inhaler performance.  
The aim of our study was to evaluate the level of adherence and the rate of inhaler 
mishandling on a cohort of elderly asthmatics, and the effect of a structured one-visit educational 
intervention on asthma control assessed after a period of 3 to 6 months. 
 
METHODS 
The EDUCA (Elderly and Device Use in Chronic Asthma) Study, a pre-post interventional 
trial with a follow-up of 3 to 6 months, promoted by the Italian Respiratory Society (IRS), was 
carried out between June 2016 and June 2017 in 21 Italian Health Service Pulmonology and Allergy 
Clinics. To be consecutively enrolled in the study, subjects were required to have a physician-
diagnosis of asthma based on 2016 GINA document (14), be 65 yrs of age or older and using a 
combination of Long-Acting Beta-2 Agonists (LABA) and Inhaled Corticosteroids (ICS) in a fixed 
dose single device or in two different devices. As by GINA 2016 (14) tiotropium was considered 
off-label for asthma, patients under treatment with tiotropium or another Long Acting Muscarinic 
Antagonist (LAMA) were excluded from enrollment. Data were recorded by researchers using a 
standardized questionnaire which included: 1) age, sex, height, weight; 2) smoking habit; 2) 
educational level; 3) the number of severe asthma exacerbations (SAEs) in the previous year, 
defined as “an asthma exacerbation requiring systemic corticosteroids for at least three days 
and/or hospitalization” (15); the device or devices in use (with the exception of that for rescue 
medication, i.e. salbutamol); the daily ICS dosage expressed as low, medium, or high dosage of 
beclomethasone dipropionate CFC or equivalent according to GINA classification (14); concomitant 
drugs for other diseases (arterial hypertension, chronic heart disease, diabetes, gastroesophageal 
reflux, osteoporosis) and the presence or arthritis on hands. In addition, the following Patient-
Reported outcomes (PROs) were assessed by validate tools a) dyspnea (modified Medical 
Research Council (mMRC) dyspnea scale (16) b) level of asthma control  (Asthma Control Test  
ACT) (17), c) health status (SF 12) (18), d) adherence to treatment (Morinsky Medication 
Adherence Scale) (19), e) anxiety and depression (Hospital Anxiety Depression Scale, HADS) (20).  
At each visit patients underwent a Forced Vital Capacity (FVC) maneuver according to the 
standardized technique (21) after proper wash-out period from bronchodilator drugs. At the end 
of the visit, patients were asked to use their device and their maneuvers were analyzed following 
the check-list reported in Table 1, modified from the Inhaler Error Steering Committee Document 
(22) we adopted when the study was designed. Whenever applicable, patients were immediately 
informed about their errors and re-checked until adequately instructed to handle correctly their 
device by physical demonstration. 
The study was approved by the Coordinating Ethic Committee of Palermo, Italy, and a 
written informed consent was collected locally for each patient. 
 
Data Analysis 
Data from each center were centralized to the investigators of Pavia, Italy (AMC), who 
were responsible for data quality control, and then submitted to the center of Milano, Italy (FDM 
and ST) for statistical analysis. The results are shown as meanstandard deviation (SD), unless 
otherwise stated.  
Lilliefors corrected K-S test was performed before the data analysis in order to examine the 
distribution of the residuals of the parametric tests. For continuous variables, two tailed paired t 
test analysis was used to analyze the difference between first and second visit in terms of errors 
done with the device in use, ACT, mMRC and SF12. Unpaired Student’s t test analysis (test for 
equal variances) was used for comparisons between patients for continuous variables; for 
dichotomous variables Chi square or Fisher’s exact test were used, as appropriate. 
Variables that resulted in p values < 0.15 were used in a multivariate logistic regression 
model to predict factors that were associated with at least one error in the use of inhaler. The 
odds ratios (OR) and their 95% confidence intervals were also derived. All tests were two-sided, 
and p < 0.05 were considered statistically significant. Asthma control was defined as optimal, 
partially or poorly controlled for ACT score ≥20, 16-19, or ≤15, respectively (23). Statistical tests 
were performed using the Statistical Package for Social Sciences (version 21.0; SPSS, Chicago, IL). 
 
RESULTS 
A total of 452 asthmatic subjects were enrolled and 411 subjects were retained for the 
statistical analysis as 41 were excluded, a) because under treatment with LAMA, b) for 
inconsistency of therapy between visit 1 and 2, and c) inclusion criteria not respected (i.e. age <65 
years).  
Table 2 summarizes demographic, clinical and functional data of the subjects. The number 
of females was higher than that of males, and an ACT score ≤19 occurred in 49% of the subjects, 
with at least one SAE in 40% of them. The devices in use were a pMDI in 41% and a DPI in 59% of 
subjects, the latter represented by Diskus (39%), Turbohaler (31%), Nexthaler (17%) and Ellipta 
(13%). The second device in use, not including salbutamol as rescue medication, was reported in a 
negligible percent of patients (36 patients, 9% of the whole population), in whom a non-fixed 
LABA/ICS combination was the option. During the first clinical evaluation (V1), at least one error 
was reported in 56% of the subjects and a low adherence was detected in 43% of them. At least 
one comorbidity was present in 80% of the subjects, and more than a quarter (30%) of them 
suffered from hand arthritis. HADS score was 7±4 and 8±4 for anxiety and depression, clinically 
relevant in 20% and 31% of the patients enrolled, respectively.  
Effect of training on the correct use of device (table 3). During follow up visit (Visit 2), both the 
percentage of patients with poor adherence and that of patients who committed at least one error 
decreased significantly (p<0.001), from 40% to 23% and from 52% to 23%, respectively. A 
significant reduction in the percentage of at least one error was reported also in the subset of 
patients with clinically relevant anxiety or depression. A parallel clinically significant increase of 
1.46±3.02 (95%CI: 1.13-1.79, p<0.001) was also observed in the ACT score (from 18.85±4.88 to 
20.32±4.04).  
Correlation between errors and asthma outcomes. Differences between subjects with at least 
one error and without any error are described in table 4. Variables that were significantly 
associated with errors were used in a multivariate logistic regression model to identify 
independent factors able to predict critical errors in the use of inhaler. As shown in Table 5, 
comorbidities, a low educational status and the presence of an asthma exacerbation in the last six 
months were factors independently associated to commit at least one error with the device.  
 
DISCUSSION 
The main findings of our study are that, in a large cohort of elderly moderate to severe 
asthmatics, half of them had features of uncontrolled disease despite optimal treatment, and that 
a similar proportion of subjects were poor adherent to treatment and misused their device. In this 
context, a one-visit educational training was shown to improve symptom control and adherence to 
inhaled therapy in subjects with at least one error in the use of their inhaler. 
The current findings are in line with the well-known poor control of asthma in the elderly 
(24). It is noteworthy that our subjects had uncontrolled asthma despite they were prescribed 
optimal treatment according to GINA guidelines. Potential explanations for the lack of asthma 
control in our cohort of elderly patients could be the well-known poor perception of dyspnea in 
the elderly (25), and low level of adherence to therapy or improper use of inhaler devices (5-6). 
The reason for the increased adherence at the follow-up visit in the absence of a specific 
intervention promoting adherence could lie in the well-recognized bias, the Hawthorn effect, 
originally described in an industrial setting (26). This suggests that the subjects’ behavior may be 
modified by the subjects’ awareness that they are being studied and for which they receive 
additional attention.  
Poor technique has been associated with age, sex, educational level and emotional 
problems (27). In asthma, device-handling errors have already been described, as well as their 
association with poor disease control (10, 20-30). A high rate of inhalation device mishandling has 
been reported in younger asthmatics, with an impact on asthma control (11, 31). In elderly COPD 
patients, high rates of inhaler device mishandling and their potential impact on COPD on 
exacerbation were recently described by Molimard et al. (32), where an underestimation of 
handling errors of device (>50% of the subjects) was associated with an increased rate of severe 
exacerbations (Odds ratio of 1.86). Moreover, data on elderly asthmatic populations are lacking, 
although Melani et al (10) reported a significant association between inhaler mishandling and 
older age.  
Recently, educational interventions of inhaler technique were reviewed (33) and found to 
be effective, at least on the short-term (with an average follow-up of 5 months). Authors 
concluded that, as expected, effectiveness of interventions holds true for patients with an 
insufficient inhaler technique, whereas interventions may be less valuable for patients with an 
already moderate to good technique. Therefore, considering constrains on budget available and 
time available, they suggested to pursue an educational intervention only in those in whom errors 
were documented, as in the present study. A recent Cochrane review on Interventions to improve 
inhaler technique (34) concluded that confirmatory trials are required, as the maximum duration 
of follow-up was only 26 weeks. Ideally, studies should report all critical descriptive statistics, and 
inhaler technique should be checked by persons blinded to group allocation. Also, the authors 
suggest to focus efforts on poor controlled asthma and/or on poor inhaler technique. Very 
recently, Maricoto et al. (13) carried out a systematic review and meta-analysis on studies 
conducted in older subjects, specifically addressing the role of education on inhaler technique on 
disease control and exacerbation rates. Although the findings confirmed the efficacy of 
educational interventions in reducing the rate of exacerbations in older individuals, the 
heterogeneity of the included studies did not allow to assess the contribution of improved inhaler 
technique education alone.  Taken together, these observations advocate for future studies 
specifically designed to compare different educational interventions on clinical outcomes in 
vulnerable populations, such as older asthmatics. From a clinical standpoint, providing the most 
suitable and efficacious time interval for regular follow-up is the main challenge. 
The presence of comorbidities has been demonstrated to influence quality of life in adults 
with asthma (35), which in turn can affect adherence to treatment. In this context, specific 
comorbidities may also impair the ability to use inhalation devices, such as arthritis.  
Some limitations should be considered in the interpretations of our results. First, this is an 
open (not blinded) study, with a lack of a control group and, as such, both patients' behaviors and 
researchers' judgements could have been influenced to some extent. However, the collection of 
the items in a single database and the analysis of the data were conducted by two independent 
teams. Second, the results are limited to a very short period of observation and cannot be 
extrapolated to longer lengths of time: the 6 months effects on adherence due to the targeted 
intervention may potentially vanish afterwards as expected by findings from other real life studies 
on duration of adherence. Third, the educational action was conducted during outpatient visits by 
well-trained pulmonologists and allergists, which may have affected the outcomes. Moreover, one 
can observe that not all errors are similar. For example, failure to remove the inhaler cap is a 
critical error, as opposed to failure to hold the inhaler upright. However, the document of the 
Inhaler Error Steering Committee (22) did not distinguish between these two types of error and 
defined as critical an error “when a patient performs an error, displays imperfect technique or 
lacks knowledge on usage or maintenance of the inhaler device that is likely to significant impair 
the delivery of adequate medication on all occasions”. However, recently Price et al (36) were able 
to identify in the CRITIKAL Study which errors are critical, meaning that they negatively impact on 
asthma outcomes. In our study, the most frequent error for the MDI device was “activating before 
inspiring” (36%), and for DPI “not inspiring with proper velocity” (32%), both of which were 
demonstrated to be correlated with uncontrolled asthma in the CRITIKAL study (36). Also 
“inspiring too quickly” (25%), “not handling correctly (16%) and “activating at the end of 
inspiration” for MDI, were judged as critical in the study by Price et al. (36). 
In conclusion, we found that a one-visit targeted educational intervention may enhance 
asthma control in the elderly, presumably by increasing adherence to treatment and inhaler 
techniques. The intervention is effective also in patients with clinically relevant anxiety and 
depression, which have been associated to a lower confidence in device usage (37). A check-list for 
potential critical errors may be helpful to identify the subjects candidates to educational efforts. 
This work was supported by Grant from Società Italiana di Pneumologia/Italian Respiratory 
Society. 
Table 1. Check list for detecting errors with the device in use (modified from ref. 22) 
MDI device  
 Do not remove cap 
 Do not handle correctly  
 Activates before inspiring 
 Activates at the end of inspiration 
 Do not activate 
 Do not inspire 
 Inspires too quickly 
 Inhales nasally 
 
DPI device 
 Do not remove cap  
 Do not charge the dose correctly 
 Charges the dose, but inverts the device before inhaling 
 Charges the dose, but shakes the device (as a MDI) 
 Expires (instead inspiring) 
 Do not connect correctly with the mouthpiece of the device 
 Do not inspire with proper velocity 
 Do not inhale orally 
 Inhales nasally 
Is not able to understand when the device is empty 
Table 2. Demographic, clinical and functional data of the study subjects. 
 
All patients 
(n=411) 
Age, yrs 72 ±5 
Male/female, n (%) 173 (42)/238 (58) 
BMI, kg/m2 27±5 
BMI≥30, n (%) 89 (22) 
Smoke History  
Current/former/no smoke, n (%) 26 (6)/147 (36)/236 (57) 
Pack-years 18 ±17 
>20 P/Y, n (%) 46 (37) 
Subjects with SAE, n (%) 167 (40) 
Education  
Primary School, n (%) 113 (29) 
Secondary, n (%) 149 (37) 
High school, n (%) 105 (26) 
Degree, n (%) 31 (8) 
Lives alone, n (%) 72 (17%) 
mMRC, (median, IQR) 1 (1-2) 
ACT, score 19±4.7 
ACT≤19, n (%) 197 (49) 
FEV1, % predicted 80±24 
Comorbidity, n (%) 334 (81) 
Hand Arthritis, n (%) 113 (30) 
Clinically relevant depression, n (%) 81 (20) 
Clinically relevant anxiety, n (%) 129 (31) 
Morinsky, score 1.03±0.96 
Data are expressed ad mean±standard deviation if not otherwise stated. mMRC: modified Medical Research Council 
dyspnea score; SAE, Severe Asthma Exacerbation. ACT: Asthma Control Test; Comorbidity: any of gastroesophageal 
reflux, arterial hypertension, osteoporosis, heart disease; IQR: interquartile range. Clinically relevant 
depression/anxiety: evaluated with HADS scale 
Table 3. Effects of educational training on outcome variables (N=318 patients). 
 Visit 1 Visit 2  Mean±SD (95% CI) p value 
Error, n 0.74±1.02 0.38±0.56 -0.37± 0.88 (0.26-0.47) <0.001 
Error ≥1, n (%)   
 
 
 All patients 167 (52) 102(32)  <0.001 
 Patients with 
clinically 
relevant 
anxiety or 
depression at 
visit 1 
74 (66) 49 (42)  <0.001 
Low Adherence, n 
(%) 
130 (41) 74 (23)  <0.001 
SF-12     
PCS 38.90±10.36 40.16±10.21 1.27±7 (0.48-2.05) <0.001 
MCS 48.03±10.92 50.73±10.07 2.69±7.96 (1.81-3.58) <0.005 
ACT 18.85±4.88 20.32±4.04 1.46±3.02 (1,13-1,79) <0.001 
mMRC 1.33±0.99 1.09±0.88 0.24±0.63 (0.17-0.31) <0.001 
Data are expressed and mean±standard deviation if not otherwise stated. mMRC: modified 
Medical Research Council dyspnea score; SF12: Short Form Health Survey; PCS: Physical Health 
Composite Score; MCS: Mental Health Composite Score; ACT: Asthma Control Test; SD: standard 
deviation. p< 0.050 in bold. Two tailed paired t test analysis for continuous variables and Chi 
square test for dichotomous variables. 
Table 4. Characteristics of enrolled patients according to the presence of at least one error in the use of inhaler 
 
Without any error 
N=181 
With at least one error 
N=230 
mean (95%CI) OR (95%CI) p value° 
 Age, yrs 
72±5 72±6 0,74 (-1.82-0.32)  0.171 
Gender, female, n (%) 
74 (43) 92 (41)   1.16 (0.75-1.61) 0.613 
Higher education*, n (%) 
74 (43) 62 (27)   0.50 (0.33-0.76) 0.001 
Living alone, n (%) 
30 (17) 43 (19)  1.18 (0.70-1.98) 0.600  
Poor adherence to therapy**, n (%) 
130 (56) 49 (27)  3.05 (2.30-5.30) <0.001 
SAE ≥1, n (%) 
46 (25) 121 (53)  3.36 (2.18-5.17) <0.001 
Comorbidity, n (%) 
132 (73) 202 (87)  2.41 (1.40-4.13) <0.001 
BMI ≥ 30 Kg/m2 53 (30) 567(30) 
 1 (0.65-1.57) 
0.810 
Rhinitis, n (%)  106 (62) 114 (50) 
 0.63 (0.42-0.94) 
0.026 
DPI, n (%) 105 (58) 137 (60)  1.09 (0.74-1.61) 0.687 
MDI, n (%) 
76 (42) 93 (40)  0.92 (0.62-1.36) 0.687 
Clinically relevant anxiety, n (%) 40 (22) 89 (39) 
 2.22 (1.4-3.43) 
<0.001 
Clinically relevant depression, n (%) 22 (12) 59 (26) 
 2.49 (1.46-4.25) 
0.001 
 
*from high school, **evaluated with Morinsky scale; SAE: Severe Asthma Exacerbation; p<0.05 in bold, ° unpaired Student’s t test analysis for 
continuous variables, Chi square test for dichotomous variables, binomial logistic regression to calculate odds ratio for dichotomous variables. 
Table 5. Significant univariate and multivariate logistic regression analyses of predictors for at least one error in the use of the inhaler 
 UNIVARIATE  MULTIVARIATE 
VARIABLE OR 95% CI p* OR 95%CI p** 
Lower education 
1.97 1.30-3.01 0.001 1.77 1.13-2.77 0.012 
SAE 
3.29 2.13-4.97 <0.001 2.84 1.82-4.43 <0.001 
Comorbidity 
2.67 1.60-4.47 <0.001 2.46 1.39-4.34 0.002 
Hands arthritis 
1.16 0.75-1.82 0.493 - - - 
Poor adherence to therapy 
1.37 0.92-2.04 0.111 - -      - 
Clinically relevant anxiety 
2.22 1.43-3.43 <0.001 1.28 0.75-2.19 0.352 
Clinically relevant depression 
2.49 1.46-4.25 0.001 1.78 0.94-3.39 0.076 
p<0.05 in bold *Binomial Logistic Regression Analysis for univariate analysis, **Multiple Regression Analysis for multivariate analysis
22 
 
23 
 
 
EDUCA Study Group Collaborators 
 
Albicini F, Gini E, Department of Internal Medicine and Therapeutics, Pneumology Unit, IRCCS 
Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy; 
Benfante A, Department of Biomedicine and Internal and Specialistic Medicine (DIBIMIS), 
University of Palermo, Palermo, Italy; 
Braido F, Department of Internal Medicine, Respiratory Diseases and Allergy Clinic, University of 
Genova, Azienda Policlinico IRCCS San Martino, Genoa, Italy; 
Caminati M, Unità Operativa di Allergologia Azienda Ospedaliero-Universitaria Integrata di Verona, 
Verona, Italy; 
Costantino MT, Internal Medicine and Rheumatology Department, Azienda Sanitaria Romagna, 
Rimini, Italy; 
Cottini M, Allergy and Pneumology Outpatient Clinic, Bergamo, Italy; 
Crivellaro M, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, 
Italy; 
De Tullio R, Ospedale consorziale Policlinico di Bari, Unità di Pneumologia, Bari, Italy; 
Gini E, Department of Internal Medicine and Therapeutics, Pneumology Unit, IRCCS Policlinico S. 
Matteo Foundation, University of Pavia, Pavia, Italy; 
Grosso A, Department of Internal Medicine and Therapeutics, Pneumology Unit, IRCCS Policlinico 
S. Matteo Foundation, University of Pavia, Pavia, Italy; 
24 
 
Guarnieri G, Department of Cardiologic, Thoracic, and Vascular Science, University of Padua, 
Padua, Italy 
Lombardi C, Departmental Unit of Allergology and Respiratory Diseases, Fondazione 
Poliambulanza, Brescia, Italy; 
Patella V, Unità Operativa di Allergologia ed Immunologia, Dipartimento di Discipline Mediche, 
Battipaglia (SA), Italy; 
Pirina P, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy; 
Polverino M, Department of Pneumology and Endoscopic Unit, Ospedale Scarlato, Scafati (SA), 
Italy; 
Raccanelli R, Fondazione Salvatore Maugeri, Istituto Scientifico di Milano – IRCCS, Milano; 
Ridolo E, Department of Medicine and Surgery, University of Parma, Parma, Italy; 
Rolla G, Allergy and Immunology, AO Mauriziano Hospital, University of Turin, Turin, Italy; 
Steinhilber G, AO Spedali Civili di Brescia, Divisione di Pneumologia, Brescia, Italy; 
Vianello A, Department of Cardiologic, Thoracic, and Vascular Science, University of Padua, Padua, 
Italy; 
 
25 
 
REFERENCES 
1. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient 
education. Respir Care. 2005 Oct;50(10):1360-74; discussion 1374-5. 
 
2. Lewis A, Torvinen S, Dekhuijzien P, Chrystyn H, Watson A, Blackney M, et al. The 
economic burden of asthma and chronic obstructive pulmonary disease and the impact of 
poor inhalation technique with commonly prescribed dry powder inhalers in three 
European countries. BMC Health Serv Res. 2016; 16:251. 
 
3. Milanese M, Di Marco F, Corsico AG, Rolla G, Sposato B, Chieco-Bianchi F, Costantino MT, 
Crivellaro MA, Guarnieri G, Scichilone N; ELSA Study Group. Asthma control in elderly 
asthmatics. An Italian observational study. Respir Med 2014; 108: 1091-9. 
 
4. Janssens J, Pache JC, Nicold LP. Physiological changes in respiratory function associated 
with ageing. Eur Respir J 1999; 13: 197-205. 
 
5. Castaldi PJ, Rogers WH, Safran DG, Wilson IB. Inhaler cost and medication non adherence 
among seniors with chronic pulmonary disease. Chest 2010; 138: 614-20. 
 
6. Baptist AP, Ross JA, Yang Y, Song PXK, Clark NM. A randomized controlled trial of self-
regulation intervention for older adults with asthma. J Am Geriatr Soc 2013; 61:747-53. 
 
7. The Medicines utilization Monitoring Centre. National Report on Medicines Use in Italy. 
Year 2017. Rome: Italian Medicine Agency 2018 available on http://agenziafarmaco.gov.it, 
last access 16 March 2019 
 
8. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and 
Prevention. 2018. Available from: https://ginasthma.org/2018-gina-report-global-strategy-
for-asthma-management-and-prevention/, last access 16 March 2019 
 
9. Giraud V, Allaert FA, Roche N. Inhaler technique and asthma: feasibility and acceptability 
of training by pharmacists. Respir Med. 2011; 105:1815-22. 
 
10. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life 
and is associated with reduced disease control. Respir Med 2011; 105: 930-38. 
 
11. Molimard M, Raherson C, Lignot S, et al. Assessment of handling of inhaler devices in real 
life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16:249-
54. 
 
12. Usmani OS, Lavorini F, Marshall J, Dunlop WCN, Heron L, Farrington E, Dekhuijzen. 
Critical inhaler errors in asthma and COPD: a systematic review of impact on health 
outcomes. Respiratory Research 2018; 19:10. 
26 
 
 
13. Maricoto T, Montero L, Gama JMR, Correia-de-Sousa J, Taborda-Barata L. Inhaler 
Technique Education and Exacerbation Risk in Older Adults with Asthma or Chronic 
Obstructive Pulmonary Disease: A Meta-Analysis. J  Am Geriatr Soc 2019; 67:57-66 
 
14. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and 
Prevention. 2016. Available from: http://ginaasthma.org/ 
 
15. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA et al. An official American 
Thoracic Society/European Respiratory Society Statement. Asthma control and 
exacerbations. Standardizing endpoints for clinical asthma trials and clinical practice. Am J 
Respir Crit Care Med 2009; 180: 59-99. 
 
16. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988; 
93:580–86. 
 
17. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. 
Development of the asthma control test: a survey for assessing asthma control. J Allergy 
Clin Immunol 2004; 113: 59-65. 
 
18. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation 
of item selection and scoring for the SF-12 Health Survey in nine countries: results from the 
IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998; 51:1171-8. 
 
19. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication 
adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008;10: 348–
354. 
 
20. Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, et al. Detecting 
psychological distress in cancer patients: validity of the Italian version of the Hospital 
Anxiety and Depression Scale. Support Care Cancer 1999; 7: 121–7. 
 
21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al. Standardisation 
of Spirometry. Eur Respir J 2005; 26:319-38. 
 
22. Inhaler Error Steering Committee, Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, 
Rand C, Scheuch G, Bousquet J. Inhaler competence in asthma: common errors, barriers to 
use and recommended solutions. Respir Med. 2013; 107:37-46. 
 
27 
 
23. Jia CE, Zhang HP, Lv Y, Liang R, Jiang YQ, Powell H et al. The Asthma Control Test and 
Asthma Control Questionnaire for assessing asthma control: systematic review and meta-
analysis. J Allergy Clin Immunol. 2013; 131:695-703. 
 
24. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 2010; 376:801-13. 
 
25. Janssens J, Pache JC, Nicold LP. Physiological changes in respiratory function associated 
with ageing. Eur Respir J 1999; 13: 197-205. 
 
26. Roethlisberger J, W.J. Dickson. Management and the worker. Harvard University Press, 
Cambridge, MA (1939). 
 
27. Rootmensen GN, van Keimpema AR, Jansen HM, de Haan RJ. Predictors of incorrect 
inhalation technique in patients with asthma or COPD: a study using a validated videotaped 
scoring method. J Aerosol Med Pulm Drug Deliv. 2010; 23:323-8. 
 
28. Price D, Roche N, Christian Virchow J, Burden A, Ali M, Chisholm A, Lee AJ, Hillyer EV, von 
Ziegenweidt J. Device type and real-world effectiveness of asthma combination therapy: an 
observational study. Respir Med. 2011; 105:1457-66. 
 
29. Al-Jahdali H, Ahmed A, Al-Harbi A, Khan M, Baharoon S, Bin Salih S, Halwani R, Al-Muhsen 
S. Improper inhaler technique is associated with poor asthma control and frequent 
emergency department visits. Allergy Asthma Clin Immunol. 2013; 9(1):8. 
 
30. Westerik JA, Carter V, Chrystyn H, Burden A, Thompson SL, Ryan D, Gruffydd-Jones K, 
Haughney J, Roche N, Lavorini F, Papi A, Infantino A, Roman-Rodriguez M, Bosnic 
Anticevich S, Lisspers K, Ställberg B, Henrichsen SH, van der Molen T, Hutton C, Price DB. 
Characteristics of patients making serious inhaler errors with a dry powder inhaler and 
association with asthma-related events in a primary care setting. J Asthma. 2016; 53:321-9. 
 
31. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with 
decreased asthma stability. Eur Respir J 2002; 19: 246-51. 
 
32. Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, Droz-Perroteau C, 
Lassalle R, Moore N, and Girodet P-O. Chronic Obstructive Pulmonary Disease exacerbation 
and inhaler device handling: real life assessment of 2935 patients. Eur Respir J 2017; 49: 
1601794. 
 
28 
 
33. Klijn SL, Hiligsmann M, Evers S, Roman-Rodriguez M, Van der Molen T, and Van Boven J. 
Effectiveness and success factors of educational inhaler technique interventions in asthma 
and COPD patients: a systematic review. Primary Care Respir Med 2017; 27:24. 
 
34. Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for 
people with asthma. Cochrane Database of Systemic Reviews 2017, issue 3, art no 
CD011286 doi 10.1002/14651858.CD012286.pub2. 
 
35. Tay TR, Radhakrishna N, Hore-Lacy F, Smith S, Hoy R, Dabsheck E, Hew M. Comorbidities 
in difficult asthma are independent risk factors for frequent exacerbations, poor control 
and diminished quality of life. Respirology 2016; 21: 1384-90. 
 
36. Price DB, Romàn-Rodriguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffyd-Jones 
K, Haughney J, Herichsen S, Hutton C, Infantino A, Lavorini F, Law LM, Lisspers K, Papi A, 
Ryan D, Stӓllberg B, Van der Molen T, Chrystin H. Inhaler Errors in the CRITIKAL Study: 
Type, Frequency, and Association with Asthma Outcomes. J Allergy Clin Immunol Pract 
2017; 5:1071-81 
 
37. Amin AN, Ganapathy V, Roughley A, Small M. Confidence in correct inhaler technique 
and its association with treatment adherence and health status among US patients with 
chronic obstructive pulmonary disease. Patient Prefer Adherence. 2017; 11:1205-12. 
 
 
 
